[Correspondence] Implementation of a community-based breast cancer management programme
In their Series paper, Catherine Duggan and colleagues1 state that a community-based programme for breast health is a successful example of an intervention to increase breast health-care capacity in a country like Peru. The authors indicate that 75% of breast cancers detected are in advanced stages;1 a situation that can be improved through effective and early community detection. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: Germ án Málaga, Sofia Cuba-Fuentes, Zoila Romero-Albino Tags: Correspondence Source Type: research
[Correspondence] Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply
In the randomised, phase 3 ENDEAVOR trial in patients with relapsed or refractory multiple myeloma, we showed that treatment with carfilzomib and dexamethasone compared with bortezomib and dexamethasone significantly improved progression-free survival (18 ·7 months with carfilzomib vs 9·4 months with bortezomib; hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: Meletios A Dimopoulos, Amy S Kimball Tags: Correspondence Source Type: research
[Correspondence] Carfilzomib for relapsed or refractory multiple myeloma
In the second interim analysis of the randomised phase 3 ENDEAVOR study published in The Lancet Oncology, Meletios Dimopoulos and colleagues1 found that, with long-term follow-up, patients with relapsed or refractory multiple myeloma treated with carfilzomib and dexamethasone (median 47 ·6 months [95% CI 42·5-not evaluable]) had significantly longer overall survival than those who were treated with bortezomib and dexamethasone (40·0 months [32·6–42·3]; hazard ratio 0·791 [95% CI 0·648–0·964]). Although the study was done as an open-label study because of the different d osing schedules for the two proteasome in...
Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: Tetsuya Tanimoto, Kenji Tsuda, Kumi Oshima, Jinichi Mori, Hiroaki Shimmura Tags: Correspondence Source Type: research
[Comment] Introduction to the Yale Precision Medicine Tumor Board
The Precision Medicine Tumor Board (PMTB) at the Yale Cancer Center (New Haven, CT, USA) was established to integrate tumour molecular profiling data with clinical care. The PMTB exists alongside disease-specific tumour boards at the Yale Cancer Center, and primarily serves patients with refractory disease and those with actionable somatic alterations. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: Michael Cecchini, Zenta Walther, Jeffrey L Sklar, Ranjit S Bindra, Daniel P Petrylak, Joseph P Eder, Sarah B Goldberg Tags: Comment Source Type: research
[Comment] Perspectives: call for papers
Since its launch in 2000, The Lancet Oncology has been committed to publishing content that advances clinical practice, challenges the status quo, and advocates change in health policy. During these years, the Cancer and Society section has explored the intersection between clinical practice, the portrayal of cancer in the wider world or mainstream media, and the perception of oncology with patients and an informed lay audience. In 2018, we refresh this section of the journal to focus articles on the views and experiences of clinicians in practice and the art of medicine. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: Yaiza del Pozo Mart ín Tags: Comment Source Type: research
[Comment] Complications during minimal invasive thoracic surgery: are new surgeons prepared?
The approach to surgery of the thorax has substantially evolved in the past decade. Although open techniques (thoracotomy) are still used in lung cancer surgery today, most lung resections can be safely done by video-assisted thoracic surgery. In the past 5 years, robotic-assisted thoracic surgery has also used new technology to facilitate minimal invasive surgery. In 2017, it is already well established that minimal invasive surgery to resect lung tumours provides equivalent oncological benefits to, with less pain and more rapid recovery than, open surgery procedures. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: Marcelo Cypel, Kazuhiro Yasufuku Tags: Comment Source Type: research
[Editorial] The NHS: failing to deliver on Beveridge's promise?
Just over 75 years have passed since Sir William Beveridge published his report outlining the parameters for a social welfare state for the UK, which crucially included “comprehensive health and rehabilitation services for prevention and cure of disease”. Beveridge's report inspired Labour Minister of Health Aneurin Bevan to establish the National Health Service (NHS). Although the vision of Beveridge and Bevan—to provide free, adequate, and equally accessibl e health care for all—remains in high regard today, the execution and delivery of their goal is currently falling short. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: The Lancet Oncology Tags: Editorial Source Type: research
[Articles] Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1 –2 trial
This study shows that brentuximab vedotin plus bendamustine, with a favourable safety profile, is an active salvage regimen for heavily pretreated patients with relapsed or refractory Hodgkin's lymphoma. This salvage regimen can potentially serve as an efficacious and safe alternative to platinum-based chemotherapy before autologous stem cell transplant. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Owen A O'Connor, Jennifer K Lue, Ahmed Sawas, Jennifer E Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, Celeste Rojas, Mark Francescone, Lawrence Schwartz, Bin Cheng, Kerry J Savage, Diego Villa, Tags: Articles Source Type: research
[News] Many FDA-approved cancer drugs might lack clinical benefit
New research shows that less than half of the randomised controlled trials (RCTs) that support the approval of anticancer drugs by the US Food and Drug Administration (FDA) reach the threshold for clinical benefit as defined by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Manjulika Das Tags: News Source Type: research
[News] PEGPH20 for metastatic pancreatic ductal adenocarcinoma
Pegvorhyaluronidase alfa (PEGPH20) —which can aid drug absorption by degrading hyaluronan in the tumour microenvironment—could improve progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma, according to recent results from the HALO 202 study. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Elizabeth Gourd Tags: News Source Type: research
[News] Daratumumab for untreated multiple myeloma
Results from a randomised phase 3 trial show that the addition of daratumumab to the standard treatment regimen of bortezomib, melphalan, and prednisone improves progression-free survival in patients with multiple myeloma who are ineligible for stem-cell transplantation. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Robert Stirrups Tags: News Source Type: research
[News] Improved progression-free survival in metastatic breast cancer
Addition of lapatinib to trastuzumab plus an aromatase inhibitor significantly improves progression-free survival (PFS) in patients with metastatic breast cancer, according to new research. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research
[Comment] Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era
Salvage treatments for patients with Hodgkin's lymphoma who are refractory to or have relapsed on standard chemotherapy represent an unmet medical need. The main goal of salvage therapies before autologous stem cell transplantation (ASCT) is achievement of complete remission. Currently, the proportion of patients with relapsed or refractory Hodgkin's lymphoma achieving a complete response with standard second-line chemotherapy ranges from 17% to 76% in different studies, depending on how many lines of therapy patients had previously received or the presence of other risk factors. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Umberto Vitolo, Annalisa Chiappella Tags: Comment Source Type: research
[News] CAR T-cell therapy in refractory large B-cell lymphoma
Recently published results have shown that axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is active and safe in patients with refractory large B-cell lymphoma. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 14, 2017 Category: Cancer & Oncology Authors: Robert Stirrups Tags: News Source Type: research
[News] TAS-102 in metastatic colorectal cancer
A new study has found that trifluridine/tipiracil (TAS-102)significantly increases overall survival compared with that for placebo in Asian patients with advanced colorectal cancer, irrespective of whether they have been exposed to biological therapy. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 14, 2017 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research
